HC Wainwright Expects Weaker Earnings for Xeris Biopharma

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for Xeris Biopharma to $0.01 from $0.02, while projecting $0.00 for Q4 2026 and $0.11 for fiscal 2027.
• Xeris reported a quarterly loss of $0.18 per share, missing the $0.01 consensus estimate by $0.19, although revenue of $92.1 million exceeded expectations of $90.12 million.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $10.80; shares recently opened at $7.93, while insiders sold approximately $2.0 million of stock over the last quarter.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Xeris Biopharma in a research report issued on Friday, August 7th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.01 per share for the quarter, down from their previous forecast of $0.02. The consensus estimate for Xeris Biopharma's current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Xeris Biopharma's Q4 2026 earnings at $0.00 EPS and FY2027 earnings at $0.11 EPS.

A number of other research analysts have also recently commented on the stock. Wall Street Zen cut shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Weiss Ratings raised shares of Xeris Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 23rd. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $10.80.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS opened at $7.93 on Monday. The stock's 50-day moving average is $7.68 and its 200 day moving average is $6.79. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -72.09 and a beta of 0.66. Xeris Biopharma has a 1-year low of $5.25 and a 1-year high of $10.08. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to analysts' expectations of $90.12 million. Xeris Biopharma had a positive return on equity of 158.10% and a negative net margin of 5.12%.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma in the 4th quarter worth $25,000. KBC Group NV bought a new position in shares of Xeris Biopharma during the first quarter valued at about $27,000. State of Wyoming purchased a new stake in shares of Xeris Biopharma during the second quarter worth about $52,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company's stock worth $59,000 after purchasing an additional 7,421 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Xeris Biopharma by 179.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company's stock worth $63,000 after purchasing an additional 5,000 shares during the period. 42.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Xeris Biopharma

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the sale, the director owned 126,500 shares of the company's stock, valued at approximately $770,385. This represents a 11.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dawn Halkuff sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $121,800.00. Following the completion of the transaction, the director owned 95,000 shares in the company, valued at $578,550. This represents a 17.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 266,499 shares of company stock worth $1,996,417 over the last quarter. Company insiders own 4.35% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source